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SUMMARY: Colorectal cancer (CRC) is the third most common cancer in the world, and mortality has remained the same for the past 50 years,
despite advances in diagnosis and treatment. Because significant numbers of patients present with advanced or incurable stages, patients with pre-
malignant lesions (adenomatous polyps) that occur as  result of genetic inheritance or age should be screened, and patients with long-standing inflammatory
bowel disease should undergo surveillance. There are different risk groups for CRC, as well as different screening strategies. It remains to be determined
which screening protocol is the most cost-effective for each risk catagory. The objective of screening is to reduce morbidity and mortality in a target
population. The purpose of this review is to analyze the results of the published CRC screening studies, with regard to the measured reduction of
morbidity and mortality, due to CRC in the studied populations, following various screening procedures. The main screening techniques, used in
combination or alone, include fecal occult blood tests, flexible sigmoidoscopy, and colonoscopy. Evidence from the published literature on screening
methods for specific risk groups is scanty and frequently does not arise from controlled studies. Nevertheless, data from these studies, combined with
recent advances in molecular genetics, certainly lead the way to greater efficacy and lower cost of CRC screening.
DESCRIPTORS: Colorectal cancer. Screening. Sigmoidoscopy. Colonoscopy. Fecal occult blood testing.
Colorectal cancer (CRC) is the
third most common malignancy in the
U.S.1 and is the second most important
cause of cancer-related mortality2.
Nearly 20 000 CRC cases were newly
diagnosed in Brazil in 1998, and an es-
timated 6 000 Brazilians would have
died of the disease by the end of that
year3. The overall five-year mortality
rate remains 50%,  unchanged over the
last few decades (Fig. 1). Recent ad-
vances in operative techniques and ad-
juvant treatment have resulted in mod-
est or no impact for patients with ad-
vanced disease4,5.
By the time symptoms of CRC oc-
cur, the majority of patients are found
to have advanced disease. Considering
the large numbers of people affected,
and based on the consistent findings of
lack of regression of cancer-related
mortality — e.g. 60 000 annual deaths
in the U.S.6 — several investigators
have concluded that development and
improvement of CRC screening meth-
ods should become a top priority in or-
der to reduce specific mortality.  Con-
sequently, over the past few years, spe-
cial attention has been given to the
modalities of CRC screening and their
application in normal and elevated risk
populations—including evaluations of
their use alone as well as in combina-
tion. In view of the importance of these
evaluations for determining the effi-
cacy of CRC screening strategies, it is
imperative that screening programs be
carried out correctly.
DEFINITIONS
Screening is the program for effec-
tive use of relatively simple and inex-
pensive tests in a large population of
asymptomatic individuals, in order to
identify those with elevated risk of can-
cer or a premalignant lesion. Only in-
dividuals testing positive in the screen-
ing test will then, undergo the more
expensive and complex diagnostic
work-up7. It must be clarified that the
main objective of these tests is not di-
agnosis or evaluation of the progres-
sion of the  disease, although these
findings definitely occur. Rather, the
main purpose of screening techniques
is to reduce specific mortality of the
studied population; therefore, if reduc-
tion in specific mortality cannot be
measured, the benefit related to the
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method cannot be demonstrated. Any
benefit associated with a screening pro-
gram must be ideally compared to an
unscreened population—a control
group. At the end of the study, if bet-
ter cancer-related survival is obtained,
a cost-effectiveness evaluation must be
performed.
There is little doubt that earlier di-
agnosis of CRC will result in better
survival. Patients with stage I lesions 8
(TNM classification —American Joint
Committee on Cancer-AJCC/Union
Internationale Contre Cancer-UICC)
exhibit a 90% five-year survival rate,
whereas mean survival rates after five
years of patients with stage IV disease
is 10%.
Elevated lesions of the large bowel
mucosa are generally called polipoyd
lesions or polyps and can exhibit sev-
eral histologic characteristics.9 It is well
established that most cases of CRC
originate from adenomatous polyps in
a relatively well known process that
develops over several years10 (Fig. 2).
This characteristic of CRC provides the
opportunity for detection and preven-
tion of disease progression through en-
doscopic recognition and excision of
adenomatous polyps, malignant pol-
yps, and some early cancers.
A significant segment of the popu-
lation has an elevated risk of develop-
ing CRC due to genetic predisposition.
These individuals may benefit from
screening early in their lives by differ-
ent methods than those designed for
the general population. Surveillance is
the term more commonly used to de-
fine screening methods for patients
with more than average risk for CRC.
Principles of CRC screening - The
following principles for screening pro-
grams are recommended by the World
Health organization (WHO)11:
1) The disease under investigation
should represent a major health
problem leading to substantial mor-
bidity and mortality;
2) The natural history of the disease
should be known at large, and the
detection of premalignant or as-
ymptomatic phases should be pos-
sible by preexisting methods.
Readily available, full diagnostic
investigation should be provided
for individuals with positive screen
tests;
3) Methods should be sensitive and
safe, and their application should
reduce disease incidence;
Figure 1  - Colorectal cancer: evolutive mortality. Source: National Cancer Institute (NCI) Public
Use Files (USA).
Figure 2  - Adenoma-carcinoma sequence.
4) A target population must be previ-
ously defined;
5) Screening costs should be consid-
ered part of preventive efforts.
METHODS
Fecal occult blood testing
(FOBT) - The rationale for CRC de-








REV. HOSP. CLÍN. FAC. MED. S. PAULO 55(1):35-42, 2000JANUARY-FEBRUARY
tic lesions bleed more than the normal
intestinal mucosa. The amount of
blood detected increases with the size
of the lesion as well the stage of the tu-
mor. FOBT provides an indirect sign of
the presence of lesions, which may not
be neoplastic and also may not be lo-
cated in the large bowel. Furthermore,
bleeding from neoplasms may be inter-
mittent. Therefore, patients with a posi-
tive test must undergo diagnostic evalu-
ation through double contrast enema or
colonoscopy9.
A study conducted in Denmark in
1985 involved approximately 65 000
individuals aged between 45 and 74
years who underwent FOBT twice
within an interval of 2 years. A sensi-
tivity rate of 52% was obtained, and
results after a ten-year follow-up pe-
riod indicated that a 52% reduction in
mortality was achieved13. In Brazil,
Habr-Gama et al.7 conducted a
multicenter FOBT study that com-
prised 3 000 individuals. Diagnostic
evaluations were performed on more
than 70% of FOBT positive partici-
pants who voluntarily participated. Of
the 88 patients with a positive test who
underwent the complete diagnostic
evaluation, ten cases of CRC were di-
agnosed, corresponding to a 11.3% risk
of cancer among patients with positive
test7.
These results seem to confirm the
widely accepted notions about the ef-
ficacy of FOBT for CRC screening.
Although FOBT represents a relatively
simple and therefore acceptable proce-
dure, its lack of sensitivity may com-
promise wide application. Similarly, its
relatively low specificity may result in
a high operational cost due to the need
for colonoscopy to rule out cancer in
patients with false-positive tests.
Flexible sigmoidoscopy - Flexible
sigmoidoscopy using a 60-cm instru-
ment will detect polyps of varying his-
tology and neoplastic potential in up to
23-38% of patients screened. As a
screening tool, sigmoidoscopy has the
following advantages when compared
to FOBT: 1) allows direct visualization
of colorectal mucosa (Fig. 3); 2) de-
tected lesions can be biopsed or ex-
cised during the exam; 3) it has a high
sensitivity and specificity for polyps in
the examined segments9. The main dis-
advantage of sigmoidoscopy is that
only the left colon is within the reach
of the scope; therefore, colonoscopy is
indicated for patients with diagnosis of
polypoid lesions or cancer at sigmoi-
doscopy.
There are no data from prospective
randomized trials designed to evaluate
the role of sigmoidoscopy in CRC
screening. Nevertheless, evidence from
case-control studies indicate that sig-
moidoscopy screening can reduce
CRC-specific mortality. Selby et al14
identified a reduction of 59% in mor-
tality for CRC diagnosed in colon seg-
ments within the reach of sigmoidos-
copy.
Although recent reviews have dem-
onstrated that screening with sigmoido-
scopy leads to the discovery of early
curable cancers and premalignant pol-
yps that can be removed (and conse-
quently to a 70 – 79% reduction in oc-
currence of fatal CRC in the distal co-
lon), sensitivity, specificity, and predic-
tive values for sigmoidoscopy are yet
to be defined.
Colonoscopy - Visualization of the
entire colon by colonoscopy obviously
remains the gold standard for detecting
and removing colonic neoplasms, and
colonoscopy has the potential to extend
the benefit offered by sigmoidoscopy.
However, full mechanical preparation
of the colon and conscious sedation are
required for adequate examination.
During colonoscopy, air insufflation of
the bowel loops is necessary for care-
Figure 3 -  Rigid and flexible sigmoidoscopes.
38
REV. HOSP. CLÍN. FAC. MED. S. PAULO 55(1):35-42, 2000 JANUARY-FEBRUARY
ful observation and examination, and
insufflation rarely lasts more than ten
minutes. In comparison to FOBT,
which has a low sensitivity for detec-
tion of small lesions, and to sigmoido-
scopy, which permits only distal colon
observation, colonoscopy is the supe-
rior method. Furthermore, colonoscopy
provides prompt removal of premalig-
nant lesions throughout the
colorectum. Colonoscopy provides a
high degree of sensitivity to a screen-
ing protocol but also adds considerably
to the overall costs. Data suggest that
the initial colonoscopy may be the
most important factor in reducing the
risk of subsequent cancer: after
colonoscopy, the patient may not be at
a greater risk than the normal popula-
tion within the same age group15.
Definition of risk groups for CRC
As a consequence of better knowledge
about the development of CRC and of
data from population and molecular
genetic studies, there is a better under-
standing and more accuracy when con-
sidering the risk of CRC for a given in-
dividual.
Nearly 75% of the normal popula-
tion are considered to be in a so-called
“normal risk” group for CRC. The re-
maining 25% individuals belong to the
“elevated risk” group. They include:
1. patients with inflammatory bowel
disease (ulcerative colitis and
Crohn’s disease) — 1%;
2. individuals with diagnosis of famil-
ial adenomatous polyposis (FAP)
—1%;
3. patients with diagnosis of heredi-
tary nonpolyposis colorectal cancer
(HNPCC) — 5%.
4. individuals with a family history of
CRC in a first degree relative, but
without any  known inherited ge-
netic defect—15 to 25%15.
Some historical case-control stud-
ies have found that there is a two to
four times increased risk of CRC when
there is a family history of CRC, al-
though the issue is still controver-
sial16,17. Consequently, for a single in-
dividual, it is important to scrutinize
the family history to determine whether
it fulfills Amsterdam’s criteria for
HNPCC18 (Table 1). For the group of
individuals from families suspected of
harboring HNPCC, the screening mo-
dality must be different from the pro-
tocol that would be used for patients
with a positive family history of only
one first degree relative, for example.
Genetic testing for HNPCC is currently
limited to research facilities and is not
yet generally available.
CRC screening strategies -
Screening the entire adult population
by colonoscopy is clearly not currently
feasible, so better ways of defining
subgroups that are at risk have become
Figure 4  -  Videocolonoscope. Insertion tube (left) and complete set (right): insertion tube, monitor,
light source, and image processor.
Table 1  - Amsterdam’s criteria to the diagnosis of family history of hereditary
nonpolyposis colorectal cancer (HNPCC).
1. Identification of three or more relatives with CRC, and
2. Two of whom are first-degree relatives of the third;
3. At least two generations are involved;
4. One person diagnosed with CRC before age 50.
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necessary in order to make optimal use
of the available resources. Although the
potential exists to achieve a better sur-
vival rate through the use of one
screening modality or the use of two or
more modalities in combination, the
feasibility, availability of technology,
costs, and adherence to protocol of
both medical personnel and patient
must be evaluated.
As result of prospective random-
ized as well as case-control studies9,15,
some strategies of CRC screening were
published in 1997 and adopted by the
American Cancer Society, American
College of Gastroenterology and
American Society of Colon and Rec-
tal Surgeons. These strategies are based
on the following principles:
1. individuals with symptoms or signs
of CRC qualify for an appropriate
diagnostic work-up, and they are
not candidates for screening meth-
ods;
2. individual or family risk of CRC
must be scrutinized on the basis of
the current knowledge of hereditary
CRC, and these risks must be de-
termined before screening starts;
3. CRC and polyp screening must be
offered to the average male and fe-
male population at  the age of 50;
4. diagnostic work-up must follow
positive screening tests;
5. inflammatory bowel disease and
personal history of CRC indicate
the need for surveillance by  differ-
ent methods;
6. screening strategies must include
efforts to increase patients’ and
health professionals’ adherence;
7. adequate information to the popu-
lation about risks and benefits as-
sociated with CRC screening meth-
ods must be provided, and full un-
derstanding must be assured.
People at average risk (everyone
at age 50) - For these individuals, an
annual FOBT or flexible sigmoidos-
copy at five-year intervals is recom-
mended for screening—either by one
or both methods.
Approximately 70–80% of all CRC
occur among people at average risk.
Average risk is defined by default as
anyone who is not otherwise defined as
being at elevated risk as defined below.
The role of sigmoidoscopy in re-
ducing CRC-associated mortality is
based on evidence provided by case-
control studies14,19,20 . The disadvan-
tages associated with this strategy are
the impossibility of total colon evalu-
ation with sigmoidoscopy and the dis-
comfort of the exam to the patients.
Although the combination of FOBT
and sigmoidoscopy is recommended as
an alternative screening protocol, there
is little or no evidence of benefit asso-
ciated with this strategy .
People at elevated risk  - Family
history of familial adenomatous poly-
posis (FAP).
Individuals with family history of
FAP must receive genetic counseling
and consider genetic tests to detect the
presence of APC (adenomatous poly-
posis coli) gene germline mutation. For
an individual with a family history of
FAP, a negative test for this mutation
rules out inheritance of the mutant
gene. For  individuals with positive or
indeterminate tests, flexible sigmoido-
scopy at 12-month intervals must be
offered starting before puberty with the
objective of identifying gene expres-
sion through the phenotype of multiple
colon adenomatous polyps. Individuals
with FAP develop hundreds to thou-
sands of colonic adenomas that will
become cancerous unless the colon is
surgically removed.
Family history of hereditary non-
polyposis colorectal cancer (HNPCC)
- People with a family history of CRC
in three or more family members, two
of whom are first-degree relatives of the
third, involving people in at least two
generations, and with one person diag-
nosed with CRC before age of 50 years
(Table 1) must receive genetic counsel-
ing and consider genetic testing for
HNPCC. For these individuals at el-
evated risk, total colon evaluation
through colonoscopy must be offered
every one or two years starting between
ages 20 and 30 and annually after 40
years of age. HNPCC cancers do not
usually arise from polyps, are frequently
multiple, occur at young age, and are
proximal to the splenic flexure21.
Individuals with inflammatory
bowel disease - For patients with long-
standing ulcerative colitis, colonoscopy
should be offered annually after eight
years from the start of pancolitis and
after 13 to 15 years from the start of
left-sided colitis until colectomy. How-
ever, no demonstrated  benefit has yet
been associated with this strategy9.
Individuals with family history of
CRC or adenomatous polyp - For
these individuals, the average risk
population strategy (see 6.1) must be
offered starting at the age 40. Whether
patients with a family history of CRC
or adenomatous polyps (not associated
with HNPCC or FAP) are at increased
risk of developing CRC has not yet
been convincingly demonstrated and
remains controversial.
Personal history of adenomatous
polyp excision - After endoscopic re-
moval of one or more adenomatous co-
lonic polyps, the first surveillance
colonoscopy must follow after a three-
year interval. After a negative result,
the next exam must be made after five
years.
Personal history of curative-intent
resection of CRC -  The objective of
follow-up after resection of CRC is to
detect recurrences, synchronic cancers,
and metachronic cancers or adenomas.
After a complete preoperative
colonoscopy during the diagnostic
phase of a CRC, total colon evaluation
must follow after a three-year interval,
and if negative, after five years9.
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CONCLUSIONS
There is reasonable evidence to in-
dicate that individuals experience ben-
efits from the early detection of CRC
and polyps as result of the application
of these screening methods. Follow-up
results from the few available prospec-
tive randomized trials indicate that
there is a better survival rate associated
with the screened groups compared to
unscreened groups9,15.
Although we do not yet have
enough data to compare the various
methods for screening, some of the
specific mortality associated with CRC
can be prevented by screening.  The
best association between a specific risk
group and the most efficient method
remains to be determined. The three
main methods used for CRC screening
are: FOBT, flexible sigmoidoscopy,
and colonoscopy—used individually or
in combination.
Although it is inexpensive and eas-
ily done, FOBT suffers from low
sensitvity and specificity. Cancer detec-
tion rates by this method are lower than
the estimated rates for a considered
population based on colonoscopy data.
Screening colonoscopy is best indi-
cated in elevated risk group individu-
als, such ulcerative colitis patients or
individuals from HNPCC suspected
families9,21, although the true efficacy
of this approach is still to be demon-
strated. There are no reliable data about
the best intervals between screening
examinations for the elevated risk
group of individuals. For patients with
family history of CRC not related to
HNPCC, better definition of subgroups
is expected from genetic studies about
gene mutation types and its prevalence
in sporadic CRC. It is expected that
these data may result in cost reduction
and better effectiveness of screening
for these high risk kindividuals.
Case-control and descriptive stud-
ies provided the best evidence about
better survival with sigmoidoscopy-
based screening protocols14,25,26.  Al-
though sigmoidoscopy cannot provide
a full colon examination, the low sen-
sitivity associated with FOBT and the
high cost and low adherence to proto-
col associated with colonoscopy have
led to a growing choice of sigmoidos-
copy as an attractive screening tool for
average risk group individuals.
The main barriers to research and
development in the field of CRC screen-
ing methods and strategies include:
– the complexity associated with the
planning of large prospective ran-
domized trials including average
and specific risk populations;
– the necessity to measure the effec-
tiveness and costs associated with
the application of a specific screen-
ing tool; and
– controversies about definitions of
average and elevated risk groups.
Attempting to establish what must
occupy the mind of physicians when
screening any one individual, we un-
derstand that there is a need for a more
sensitive test than FOBT, a less inva-
sive and less expensive method than
colonoscopy, and a more comprehen-
sive examination than sigmoidoscopy.
The high prevalence and significant
morbidity and mortality resulting from
CRC throughout the world and in Bra-
zil as mentioned above, associated with
the unequivocal benefit associated with
the early detection of CRC may lead to
the consideration of CRC screening as
a high priority research issue within
public health affairs.
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O câncer colorretal (CCR) é a ter-
ceira neoplasia mais freqüente no mun-
do. A mortalidade persiste inalterada
nos últimos 50 anos a despeito dos
avanços obtidos em diagnóstico e tra-
tamento. Significativa parcela dos do-
entes se apresenta com tumores em es-
tágio avançado ou incuráveis de onde
se depreende a necessidade de ras-
treamento dos pacientes com lesões
pré-malignas (pólipos adenomatosos)
como resultado de herança genética ou
idade, e de vigilância dos portadores de
doença inflamatória intestinal de lon-
ga evolução. Na medida em que exis-
tem diferentes grupos de risco iden-
tificáveis para CCR e diferentes estra-
tégias para o rastreamento, há que se
determinar o protocolo de triagem ca-
paz de oferecer maior relação custo-be-
nefício. Uma vez que o objetivo das
técnicas de rastreamento é diminuir a
morbi-mortalidade da população ana-
lisada, o presente trabalho objetiva co-
nhecer, sob essa perspectiva, os resul-
tados dos estudos disponíveis até o
momento para o rastreamento do CCR.
Os principais métodos de rastreamento
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incluem, isoladamente ou em associa-
ção, o emprego da pesquisa de sangue
oculto nas fezes, a sigmoidoscopia e o
exame colonoscópico. As evidências de
literatura a respeito dos métodos de
rastreamento para os diversos grupos
de risco específicos são insuficientes e,
freqüentemente, não envolvem estudos
controlados. A necessidade de realiza-
ção desses estudos associada ao pro-
gresso nos estudos de genética mole-
cular resultará em maior eficácia e me-
nor custo associados ao rastreamento
do CCR.
DESCRITORES:  Câncer colorretal.
Rastreamento.  Sigmoidoscopia.
Colonoscopia. Pesquisa de sangue
oculto nas fezes.
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